1. Search Result
Search Result
Results for "

3D

" in MCE Product Catalog:

1675

抑制剂 & 激动剂

11

化合物筛选库

3

荧光染料

128

生化试剂

12

多肽产品

5

MCE 试剂盒

4

抗体抑制剂

19

天然产物

38

重组蛋白

1249

同位素标记物

29

抗体

11

点击化学

37

寡核苷酸

没找到您心仪的产品?我们拥有更多针对信号通路的抑制剂、激动剂、调节剂

您还可以尝试以下方式,我们的专业人员为您服务

Cat. No. Product Name
  • HY-L903
    5,400 compounds

    基于片段的药物发现(FBDD)作为发现新药的有力方法,已备受制药行业和学术界关注。 在近期上市的药物结构中,sp3 中心和立体中心的比例显著增加,研究者们对高三维度(3D)和富含 Fsp3 中心的片段库颇感兴趣。

    MCE 3D 多样片段库由 5,400 个非平面片段分子组成(平均 Fsp3 值为 0.58),超过4,700个片段至少包含一个手性中心。本库设计的关键元素是 3D 结构、多样性、生物反应性等。另,库中化合物在保证高sp3中心和 3D 结构优势的同时,还有效提高了片段潜在生物活性,为基于片段的药物发现提供了更高的片段命中优化概率,增加了找到创新命中的可能性。

  • HY-L923
    9000 compounds

    离子通道是细胞膜上调控离子跨膜流动的关键蛋白,广泛参与神经传导、肌肉收缩、心跳节律、疼痛感知等几乎所有生理过程。其功能异常会导致心律失常、癫痫、高血压、神经性疼痛、癌症等多种重大疾病,因此离子通道是公认的重要药物靶点---目前全球已有超过15%的上市药物以离子通道为作用靶点,在心血管、神经、镇痛等领域具有不可替代的治疗价值。

    MCE汇集了5000多种报道的离子通道相关活性化合物,主要靶向 Na+ 通道、K+ 通道、Ca2+ 通道、GABA 受体、iGluR 等,通过AI模型对化合物进行2D(分子指纹、药效团)和3D(空间构象)双重表征,筛选出与已知活性分子高度相似的结构类似物。同时,运用整合了XGB与ISE图谱策略的hERG通道预测算法,对化合物库进行全面的潜在心脏毒性评估并剔除,这一步骤可显著降低后续筛选中的安全性隐患,尤其对心血管相关离子通道药物研发(如 Nav1.5、Cav1.2)具有重要意义,能有效减少因 hERG 抑制导致的研发失败,是筛选离子通道药物的有用工具。

  • HY-L0079V
    2,470 compounds
    A specially synthesized set of 2 compounds able to mimic glycosides and their interaction with proteins. The main emphasis of library design was made on drug-like compounds enriched with H-bond donors (possess at least two H-bond donors) and bearing nature-like Fsp3–rich scaffolds with diverse spatial orientation of H-bond donors and different 3D-shapes.
  • HY-L033
    387 compounds

    拟肽化合物是一类药效团在三维空间中模拟天然肽或蛋白质,并保留与生物靶标相互作用的能力,产生相同的生物效应的化合物。拟肽化合物的设计是为了规避一些天然肽自身存在的问题:如对蛋白水解作用的稳定性(活性持续时间)和较差的生物利用度,某些其他性质,如受体的选择性或效能,往往可以得到很大的改善。拟肽的设计和合成是非常重要的,因为在分子识别和信号传递中,尤其是在生命系统中,肽和蛋白-蛋白相互作用起着主导作用。因此,拟肽类化合物在新药开发中具有巨大潜力。

    MCE 拟肽类化合物库包含 387 种小分子化合物,包括类肽,α-螺旋类似物,β-折叠类似物等,是药物发现中研究构效关系不可或缺的工具。

  • HY-L0106V
    2,906 compounds
    Protein-protein interactions (PPIs) play a key role in nearly every biological function and are a promising new class of biological targets for therapeutic intervention. This is a collection of 2,906 diverse compounds designed for discovery of PPI modulators.
  • HY-L0115V
    10,091 compounds

    ASINEX has elaborated a library of diverse macrocycles using an effective tool box of synthetic methods. The resulting scaffolds are novel, tremendously diverse, medchem-relevant, macrocyclic frameworks.

    Macrocyles tend to be larger than traditional screening molecules which make them perfect discovery tools for targets with shallow or extended binding sites. At the same time, their unique character based on restricted flexibility and ability to form intra-molecular hydrogen bonds allows for design approaches effectively optimizing properties such asaqueous solubility and membrane permeability. Many of these macrocycles have been tested for aqueous and DMSO solubility with cut-offs applied at 10 mM in DMSO and 50 µM in PBS (pH 7.4) followed by PAMPA permeability assay.

  • HY-L0104V
    1,900,000 compounds
    UORSY New Generation Screening Library contains about 1,900,000 compounds. The library is a revolutionary collection of lead-like molecules with outstanding structural quality and diversity—New Generation Screening Library (NGSL). Its core is decorated with interesting building blocks, including important medicinal fragments such as peptide bonds, amino groups and hydroxyl groups. and designed for discovery of new Voltage-gated calcium channel blockers.
  • HY-L0101V
    2,244,487 compounds
    FCH Group Screening Library Collection contains about 2,244,487 lead-like compounds for biological screening. This brand new collection comprises polar molecules with pharmacologically important groups such as free carboxylic and amino groups.
  • HY-L0080V
    1,388 compounds
    A set of 1,388 Lipoxygenase (LOX) inhibitors designed using docking and 2D similarity search.
  • HY-L0060V
    5,440 compounds
    A unique collection of 5 small molecules targeting the family of eight endothelial differentiation gene (EDG) receptors (S1P1–5 and LPA1–3) which is suitable for Lipid GPCR screening research.
  • HY-L165
    246 compounds

    多巴胺受体 (DAR) 广泛分布在大脑中,对运动功能、动机和驱动力以及认知发挥着关键的调节作用。DA 的作用由 D1 型 (D1、D5)和 D2 型受体 (D2S、D2L、D3、D4) 介导,这些受体分布在突触前、突触后和突触外、投射神经元和中间神经元中。每种受体都有不同的功能。D1 和 D5 受体与 G 刺激位点偶联并激活腺苷酸环化酶。腺苷酸环化酶的激活导致第二信使 cAMP 的产生,从而导致蛋白激酶 A (PKA) 的产生,从而导致在细胞核中进一步转录。D2 至 D4 受体与 G 抑制位点偶联,抑制腺苷酸环化酶并激活钾离子通道。这些受体利用磷酸化级联或直接膜相互作用来影响电压门控通道和神经递质门控通道、胞质酶和转录因子的功能。多巴胺受体在日常生活功能中发挥着重要作用。

    MCE 收录了 246 种多巴胺受体相关化合物,可以用于神经系统疾病药物的筛选。

Your information is safe with us. * Required Fields.

* 客户姓名:

 

* 公司或机构名称:

* Email:

 

* 联系电话:

* 产品名称:

 

* 需求量:

   目录号:

 

   CAS号:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
目录号:
需求量: